GLP-1 Peptide Atlas, by Delfa

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06948747

Org study IDD7260C00017

Timeline

Milestones

Study first posted2025-04-29actual

Study start2025-05-06actual

Primary completion2025-10-03actual

Study completion2025-10-03actual

Last update posted2025-10-10actual

Assets

Investigational agents

AZD5004 / ECC5004

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years

Maximum age55 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Healthy male and female participants aged 18 to 55 years

•All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.

•Female(s) of childbearing potential if heterosexually active, must agree to use an approved method of highly effective contraception.

•Male participants must use condoms for the duration of clinical trial.

•Additional contraception must be used for the sexual partners of male trial participants throughout the clinical trial.

•Have a body mass index (BMI) between ≥ 20.0 and ≤ 35 kg/m2 (at the time of screening) inclusive and weigh at least 50 kg.

Exclusion criteria

•History of any clinically important disease or disorder (liver transplant, liver disease, positive for serum HBsAg (Hepatitis B surface antigen) OR anti-HBcAb (Hepatitis B core antibody), positive for anti-HCV (Hepatitis C virus), history of cirrhosis and/or hepatic decompensation, cardiovascular disease, neuromuscular or neurogenic disease.

•History of Type 1 or Type 2 diabetes mellitus (DM).

•History of Hemoglobin A1c ≥ 6.5% (≥ 48 mmol/mol) at screening.

•History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.

•Any clinically important illness, medical/surgical procedure, or trauma.

•Any laboratory values with deviations or clinically important abnormalities in clinical chemistry, hematology, or urinalysis at the Screening Visit or on admission to the Clinical Unit.

•Significant hepatic disease as judged by the investigator.

•Any positive result on screening for serum HBsAg, HBcAb or HIV (Human immunodeficiency virus).

•Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12 lead ECG, at screening

•Abnormal vital signs.

•Uncontrolled thyroid disease or history/family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).

•Current smokers or those who have smoked or used nicotine products.

•Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the investigator. Excessive intake of alcohol defined as the regular consumption of more than 24 g of alcohol per day for men or 12 g of alcohol per day for females.

•Positive screen for drugs of abuse, or alcohol or cotinine at screening or on each admission to the Clinical Unit.

•History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity.

•Excessive intake of caffeine-containing drinks or food

•History of psychosis or bipolar disorder or major depressive disorder or suicide attempt or suicidal ideation.

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.